HomeList of TitleSearchContact Us
Open Journal of Cardiology

ISSN: 2075-9010
Volume 6, 2017

Indexed in:

Open Journal of Cardiology, 2013, 4-1 [Review Article]

Recent developments for surgical aortic valve replacement: The concept of sutureless valve technology

Thierry Carrel, Lars Englberger, Mario Stalder
Clinic for Cardiovascular Surgery, University Hospital Berne, Switzerland

Corresponding Author & Address:

Thierry Carrel
Chairman, Clinic for Cardiovascular Surgery, University Hospital Berne, CH-3006 Berne, Switzerland; Phone: +41 31 632 23 75; Fax: +41 31 632 44 43; Email: thierry.carrel@insel.ch

Article History:
Published: 12th January, 2013   Accepted: 12th January, 2013
Received: 5th October, 2012      

Open Journal of Cardiology, 2013, 4-1

© Carrel et al.; licensee Ross Science Publishers
ROSS Open Access articles will be distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work will always be cited properly.

Keywords: Aortic valve stenosis, aortic valve regurgitation, surgical replacement, sutureless valves


Aortic stenosis has become the most frequent type of valvular heart disease in Europe and North America and presents in the large majority of patients as calcified aortic stenosis in adults of advanced age. Surgical aortic valve replacement has been recognized to be the definitive therapy which improves considerably survival for severe aortic stenosis since more than 40 years. In the most recent period, operative mortality of isolated aortic valve replacement for aortic stenosis varies between 1-3% in low-risk patients younger than 70 years and between 4 and 8% in selected older adults. Long-term survival following aortic valve replacement is close to that observed in a control population of similar age. Numerous observational studies have consistently demonstrated that corrective surgery in symptomatic patients is invariably followed by a subjective improvement in quality of life and a substantial increase in survival rates.

More recently, transcatheter aortic valve implantation (TAVI) has been demonstrated to be feasible in patients with high surgical risk using either a retrograde transfemoral or transsubclavian approach or an antegrade, transapical access. Reported 30-day mortality ranges between 5 and 15%) and is acceptable when compared to the risk predicted by the logistic EuroSCORE (varying between 20 and 35%) and the STS Score, although the EuroScore has been shown to markedly overestimate the effective operative risk. One major concern remains the high rate of paravalvular regurgitation which is observed in up to 85% of the patients and which requires further follow-up and critical evaluation. In addition, long-term durability of these valves with a focus on the effects of crimping remains to be addressed, although 3-5 year results are promising.

Sutureless biological valves were designed to simplify and significantly accelerate the surgical replacement of a diseased valve and allow complete excision of the calcified native valve. Until now, there are 3 different sutureless prostheses that have been approved. The 3f Enable valve from ATS-Medtronic received CE market approval in 2010, the Perceval S from Sorin during Q1 of 2011 and the intuity sutureless prosthesis from Edwards in 2012. All these devices aim to facilitate valve surgery and therefore have the potential to decrease the invasivness and to shorten the conventional procedure without compromise in term of excision of the diseased valve. This review summarizes the history and the current knowledge of sutureless valve technology.

©2017 Ross Science Publishers